Inmune Bio (INMB) Cash & Equivalents (2017 - 2026)
Inmune Bio (INMB) posted Cash & Equivalents of $18.41 million for Q2 2026, down 44.8% from $33.37 million a year earlier and down 13.8% from the prior quarter.
Powered by 
Analysis
Inmune Bio (INMB) Cash & Equivalents (2017 - 2026) Analysis & Trends
At the end of FY2025, Inmune Bio's Cash & Equivalents came in at $24.75 million, up 18.3% from FY2024.
- Annual Cash & Equivalents shows a five-year compound annual growth rate of 2.4% (FY2020 to FY2025).
- In prior years, Inmune Bio's Cash & Equivalents was $20.92 million in FY2024 (-41.6%), $35.85 million in FY2023 (-31.3%), $52.15 million in FY2022 (-30.3%) and $74.81 million in FY2021 (+240.6%).
- The Q2 2026 figure stands as the lowest quarterly Cash & Equivalents since Q2 2020.
- On a year-over-year basis, Cash & Equivalents increased in three of the last eight quarters, with an average decline of 14.1%.
- The strongest year-over-year quarter for Cash & Equivalents in the past five years was Q3 2021, with growth of 247.5%; the weakest was Q1 2024, with a decline of 49.0%.
- According to Business Quant data, Cash & Equivalents for the three prior quarters was $21.36 million (Q1 2026), $24.75 million (Q4 2025) and $27.73 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,076.25 Bn | 1,044.84 Bn | 19.71 Bn | 8.95 Bn |
| 2 | Johnson & Johnson | 617.18 Bn | 535.70 Bn | 17.26 Bn | 20.42 Bn |
| 3 | AbbVie | 464.58 Bn | 437.73 Bn | 12.70 Bn | 6.57 Bn |
| 4 | Merck | 356.04 Bn | 310.47 Bn | 12.21 Bn | 6.85 Bn |
| 5 | Novartis Ag | 269.07 Bn | 224.94 Bn | 11.24 Bn | 7.62 Bn |
| 6 | Astrazeneca | 243.21 Bn | 216.77 Bn | 12.86 Bn | 4.89 Bn |
| 7 | Amgen | 217.88 Bn | 173.28 Bn | 7.24 Bn | 13.99 Bn |
| 8 | Gilead Sciences | 179.62 Bn | 153.74 Bn | 6.22 Bn | 3.18 Bn |
| 9 | Pfizer | 158.45 Bn | 105.40 Bn | 10.94 Bn | 976.00 Mn |
| 10 | Inmune Bio | 53.37 Mn | -38.88 Mn | - | 18.41 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 18.41 Mn |
| Mar 31, 2026 | 21.36 Mn |
| Dec 31, 2025 | 24.75 Mn |
| Sep 30, 2025 | 27.73 Mn |
| Jun 30, 2025 | 33.37 Mn |
| Mar 31, 2025 | 19.34 Mn |
| Dec 31, 2024 | 20.92 Mn |
| Sep 30, 2024 | 33.55 Mn |
| Jun 30, 2024 | 31.07 Mn |
| Mar 31, 2024 | 26.00 Mn |
| Dec 31, 2023 | 35.85 Mn |
| Sep 30, 2023 | 41.81 Mn |
| Jun 30, 2023 | 47.83 Mn |
| Mar 31, 2023 | 51.00 Mn |
| Dec 31, 2022 | 52.15 Mn |
| Sep 30, 2022 | 57.41 Mn |
| Jun 30, 2022 | 61.21 Mn |
| Mar 31, 2022 | 66.73 Mn |
| Dec 31, 2021 | 74.81 Mn |
| Sep 30, 2021 | 84.47 Mn |
API Access
Inmune Bio Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=INMB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "INMB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=INMB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();